2025年9月16日, 礼来 小分子GLP-1受体激动剂Orforglipron减重三期临床ATTAIN-1数据发表在新英格兰期刊上,36mg高剂量组治疗72周减重12.4%,安慰剂校正后减重幅度为11.5%。相比之下,司美格鲁肽2.4mg剂量组治疗72周减重幅度为15.1%(安慰剂校正后)。司美格鲁肽口服25mg剂量组治疗64周减重幅度为13.9%。可见,礼来小分子GLP-1受体激动剂...
Source Link2025年9月16日, 礼来 小分子GLP-1受体激动剂Orforglipron减重三期临床ATTAIN-1数据发表在新英格兰期刊上,36mg高剂量组治疗72周减重12.4%,安慰剂校正后减重幅度为11.5%。相比之下,司美格鲁肽2.4mg剂量组治疗72周减重幅度为15.1%(安慰剂校正后)。司美格鲁肽口服25mg剂量组治疗64周减重幅度为13.9%。可见,礼来小分子GLP-1受体激动剂...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.